提醒成功
微信/QQ登錄
搜索
首頁
| 產(chǎn)品規(guī)范 | |
|---|---|
| Type | In Vivo - Reseach Grade Antibody |
| Host | CHO cells |
| catalog# | B00049 |
| Application | Flow cytometry, animal model study |
| Aliases | B-lymphocyte antigen CD20, MS4A1, B1, Bp35, CVID5, LEU-16, MS4A2, S7, membrane spanning 4-domains A1, FMC7 |
| Size/Concentration | 1mg/5mg/20mg |
| Isotype | Human IgG1 kappa |
| Storage | Store at 4°C 1 month, store at -20°C to -70°C 12 month. protected from prolonged exposure to light. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Human CD20 |
| Formulation | PBS, pH 7.4 |
Description |
|---|
Obinutuzumab Biosimilar uses the same protein sequences as the therapeutic antibody obinutuzumab. Obinutuzumab is an antineoplastic CD20 antibody used to treat untreated chronic lymphocytic leukemia in combination with chlorambucil. In contrast to rituximab, which is a classic type I CD20 antibody, obinutuzumab binds to type II CD20 antibodies. This allows obinutuzumab to have a much higher induction of antibody-dependant cytotoxicity and a higher direct cytotoxic effect than the classic CD20 antibodies. |
Obinutuzumab Biosimilar, CD20 Monoclonal Antibody B00049
聯(lián)系方式
CONTACT-
聯(lián)系電話:
0731-88388785 -
公司郵箱:
-
公司地址:
湖南省長沙市高新開發(fā)區(qū)林語路239號順暢產(chǎn)業(yè)園5樓
官方微信
產(chǎn)品中心
Product技術服務
service客戶留言
message